Literature DB >> 12047020

Antipsychotic prescribing practices in the Veterans Healthcare Administration--New York metropolitan region.

Ellen M Weissman1.   

Abstract

Most research literature concerning pharmacological treatments reports results from controlled clinical trials, which provide data critical to assess the efficacy of new treatments in research populations. Fewer studies examine how treatments are adopted in everyday practice settings, where comorbid disorders and environmental issues typically complicate patients' situations. In this study, we examine the evolution of antipsychotic prescribing practices in the New York region of the Veterans Healthcare Administration (VHA) from 1998 to 2000 using administrative data. Second generation antipsychotic medications are now prescribed more frequently than the older antipsychotic medications, with a concomitant increase in cost. Data show low rates of clozapine use, relatively high rates of polypharmacy, and intersite variation in prescribing practices. Additional research in everyday practice settings is needed to address clinical questions unlikely to be answered through traditional efficacy research and to examine reasons for intersite differences in prescribing patterns.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12047020     DOI: 10.1093/oxfordjournals.schbul.a006924

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  23 in total

1.  Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia.

Authors:  Kang Sim; Alex Su; Senta Fujii; Shu-Yu Yang; Mian-Yoon Chong; Gabor S Ungvari; Tianmei Si; Eun K Chung; Hin-Yeung Tsang; Yiong H Chan; Stephan Heckers; Naotaka Shinfuku; Chay H Tan
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

2.  Does antipsychotic polypharmacy increase the risk for metabolic syndrome?

Authors:  Christoph U Correll; Anne M Frederickson; John M Kane; Peter Manu
Journal:  Schizophr Res       Date:  2006-10-27       Impact factor: 4.939

Review 3.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

4.  Trends in adult antipsychotic polypharmacy: progress and challenges in Florida's Medicaid program.

Authors:  Robert J Constantine; Ross Andel; Rajiv Tandon
Journal:  Community Ment Health J       Date:  2010-01-23

Review 5.  A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.

Authors:  William G Honer; Ric M Procyshyn; Eric Y H Chen; G William MacEwan; Alasdair M Barr
Journal:  J Psychiatry Neurosci       Date:  2009-11       Impact factor: 6.186

Review 6.  Augmentation strategies in clozapine-resistant schizophrenia.

Authors:  Gary Remington; Amitabha Saha; Siow-Ann Chong; Chekkera Shammi
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

7.  Antipsychotic Use Pattern in People with Psychotic Disorder Living in Board and Care Facilities.

Authors:  Etem Erdal Ersan; Mustafa Yildiz
Journal:  Noro Psikiyatr Ars       Date:  2015-06-01       Impact factor: 1.339

8.  Polypharmacy in the management of patients with schizophrenia on risperidone in a tertiary-care hospital in Malaysia.

Authors:  Sa Jacob; Mi Mohamed Ibrahim; F Mohammed
Journal:  Ment Health Fam Med       Date:  2013-01

9.  Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study.

Authors:  James A Kaye; Brian D Bradbury; Hershel Jick
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

10.  Prescribing practices of clozapine in India: Results of a opinion survey of psychiatrists.

Authors:  Amresh Shrivastava; Nilesh Shah
Journal:  Indian J Psychiatry       Date:  2009 Jul-Sep       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.